We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





FDA-Approved Cholesterol-Lowering Drug Could Reduce SARS-CoV-2’s Ability to Reproduce or Even Make it Disappear

By HospiMedica International staff writers
Posted on 15 Jul 2020
A FDA-approved cholesterol-lowering drug could stop SARS-CoV-2 from controlling our metabolism and potentially downgrade COVID-19’s danger level to that of a common cold.

Research by the Hebrew University of Jerusalem (Jerusalem, Israel) and Mount Sinai Medical Center (Miami, FL, USA) has revealed that the FDA-approved drug Fenofibrate (Tricor) could reduce SARS-CoV-2’s ability to reproduce or even make it disappear. More...
In a report by The Jerusalem Post, the researchers have explained that viruses are parasites and cannot replicate themselves or make new viruses, but need to enter a human cell and then hijack it. The research team which spent the last three months studying what SARS-CoC-2 is doing to human lung cells found that the novel coronavirus prevents the routine burning of carbohydrates, resulting in large amounts of fat accumulating inside lung cells - a condition required for the virus to reproduce.

The researchers believe that by understanding how the SARS-CoV-2 controls our metabolism, we can wrestle back control from the virus and deprive it from the very resources it needs to survive. A review of a panel of eight already approved drugs that could possibly interfere with the virus’s ability to reproduce revealed that Tricor caused the cells to start burning fat, resulting in the virus almost completely disappearing within only five days of treatment. According to the report, the experiment was conducted in lab studies both in Israel and New York and was replicated several times with different lung samples. The researchers are now advancing to animal studies in New York and hope to fast-track clinical studies in both Israel and the US within the next couple of weeks, as the drug is already proven to be safe.

Related Links:
Hebrew University of Jerusalem
Mount Sinai Medical Center



New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Monitoring System
AlarmSense
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.